TY - JOUR T1 - Efficacy of Tegafur-Uracil in Advanced Urothelial Cancer Patients after the Treatment Failure of Platinum-based Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 1603 LP - 1606 VL - 35 IS - 3 AU - AERKEN MAOLAKE AU - KOUJI IZUMI AU - RIE TAKAHASHI AU - SHINGO ITAI AU - KAZUAKI MACHIOKA AU - HIROSHI YAEGASHI AU - TAKAHIRO NOHARA AU - YASUHIDE KITAGAWA AU - YOSHIFUMI KADONO AU - HIROYUKI KONAKA AU - ATSUSHI MIZOKAMI AU - MIKIO NAMIKI Y1 - 2015/03/01 UR - http://ar.iiarjournals.org/content/35/3/1603.abstract N2 - Background: Platinum-based chemotherapy is the first-line treatment for advanced urinary tract urothelial cancers. However, the optimal second-line treatment is unclear. Although tegafur-uracil is sometimes used for advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy, there is little evidence regarding its use as a second-line treatment. Patients and Methods: Advanced urothelial cancer patients previously treated with platinum-based chemotherapy were retrospectively analyzed. Overall survival (OS) was compared between patients with and without tegafur-uracil treatment. Results: Thirty-one patients (27 and 4 patients with and without tegafur-uracil treatment, respectively) were analyzed. OS from the last day of the final chemotherapy course was better in patients with tegafur-uracil treatment than in those without (p<0.001, 358 and 66.5 days of the median survival time, respectively). Conclusion: Tegafur-uracil may be a candidate for the secondary treatment of advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy. ER -